Re-evaluating the effect of SARS-CoV-2 mRNA vaccination on clinical outcomes in patients treated with immune checkpoint inhibitors

Authors: Elise Dumas[1], Paul Gougis[2,3,4], Lorenzo Gasparollo[1], Jean-Philippe Spano[3], Mats Julius Stensrud[1]

Affiliations:

[1]Institute of Mathematics, École Polytechnique Fédérale de Lausanne, Lausanne, Switzerland.
[2]Residual Tumor & Response to Treatment Laboratory, RT2Lab, Translational Research Department, INSERM, U932 Immunity and Cancer, Université Paris Cité F-75005 Paris, France.
[3]Department of Medical Oncology, Pitié-Salpêtrière hospital, Sorbonne Université, Institut Universitaire du Cancer, Paris, France.
[4]Clinical Investigation Center (CIC-1901) INSERM, Department of Pharmacology, Pitié-Salpêtrière Hospital, Sorbonne Université, Paris, France.

Corresponding author:

Dr Elise DUMAS
elise.dumas@epfl.ch
EPFL SB MATH BIOSTAT (Bâtiment MA), Station 8 CH-1015 Lausanne, Switzerland
+41772874252

Disclosures

Dr Gougis reports an academic grant from Sanofi. Dr. Spano reports consultant or advisory role fees from Roche, MSD, BMS, Lilly, AstraZeneca, Daiichi-Sankyo, Mylan, Novartis, Pfizer, PFO, LeoPharma, Incyte, and Gilead and a research academic grant for MSDAvenir. Dr Stensrud. reports stock, honoraria, and consulting or advisory role from Novartis. The other authors did not declare competing interests for this work.

Abstract : SARS-CoV-2 mRNA vaccination (COVID-19 vaccination) within 100 days of immune checkpoint inhibitor (ICI) treatment was reported to improve survival and prevent disease progression in patients with non-small cell lung cancer (NSCLC) and metastatic melanoma (Grippin *et al.*, Nature, 2025). However, the clinical evidence, derived from real-world observational data, might suffer from methodological limitations, including immortal-time bias. These key limitations can be overcome by carefully designing a target trial emulation analysis. Using the data made publicly available by the authors, we emulated a target trial that would identify the causal effect of COVID-19 vaccination within 100 days of first ICI on overall survival and progression-free survival in patients with NSCLC and metastatic melanoma. In contrast to the original analysis, we found no evidence that COVID-19 vaccination improves survival outcomes in these populations. The original results likely reflect biases inherent to non-causal observational analyses. To clarify the true effect of COVID-19 vaccination in this setting, larger and suitably designed studies are needed.

Introduction

A recent widely discussed study suggests that SARS-CoV-2 mRNA vaccines (COVID-19 vaccines) may sensitize tumours to immune checkpoint blockade and increase the effectiveness of immune checkpoint inhibitors (ICIs).[1] In the study's clinical observational analysis, vaccinated patients with stage III/IV non-small cell lung cancer (NSCLC) and stage IV melanoma appeared to have lower risks of death. Specifically, survival improvements of 24.9 percentage-points were observed after 3 years in the vaccinated group compared to the unvaccinated group (55.7% versus 30.8%; adjusted hazard ratio (HR) 0.51, 95% confidence interval (CI) 0.37–0.71) in patients with NSCLC, and of 23.5 percentage-points (44.1% versus 67.6%; HR 0.37, 95% CI 0.18–0.74) in patients with stage IV melanoma. Furthermore, COVID-19 vaccination appeared to increase progression-free survival (PFS) in the stage IV melanoma cohort.

However, the study suffers from key methodological limitations that could compromise the causal interpretation of the results. These limitations could be avoided by carefully emulating a target trial within a formal framework of causal inference.[2] Target trial emulation is based on specifying a hypothetical randomized trial that would answer the research question, and then on reproducing its key components as closely as possible using the available observational data.[3] To address the methodological limitations of the original study, we emulated a target trial to evaluate the effect of COVID-19 mRNA vaccines administered within 100 days of ICI treatment on clinical outcomes, using the data from Grippin *et al*.[1]

Methods

Specification of the target trial protocol

In the hypothetical trial, we would include patients with either stage III/IV NSCLC or stage IV melanoma and initiating ICI treatment after the COVID-19 vaccines became available. Patients would be randomly assigned to one of the two interventions: (i) get a COVID-19 vaccine within 100 days of the first ICI or (ii) do not get a COVID-19 vaccine within 100 days of the first ICI. Patients would be followed from the first date of ICI up to September 2024. The primary outcomes would be overall survival (OS) at 36 months for NSCLC and OS and progression-

free survival (PFS) at 36 months for stage IV melanoma. The full protocol of the hypothetical target trial is detailed in Table 1.

Emulation of the hypothetical target trial

We emulated the hypothetical target trial using the data presented by Grippin et *al.*, which were available online for NSCLC patients and stage IV melanoma patients (dataset access: 11/01/2025). Details on the target trial emulation is given in Table 1. Briefly, we used a cloning, censoring and weighting procedure.[4] Inverse probability of censoring weights were based on baseline confounders including socio-demographic factors and comorbid conditions. The code is available online (https://github.com/elisedms/target-trial-emulation-covid-vaccine-ICI).

Results

Out of 884 patients in the original NSCLC cohort, we included 277 patients in the target trial emulation, among whom 140 (50.5%) received a COVID-19 vaccine within 100 days of first ICI (Figure 1A). Similarly, out of 210 patients in the original stage IV melanoma cohort, we included 134 patients, among whom 43 (32.1%) received a COVID-19 vaccine within 100 days of first ICI (Figure 1B). For patients with NSCLC, 3-year OS was 52.7% (95% CI 42.0–63.0) in the vaccinated arm and 46.3% (95% CI 34.9–56.5) in the unvaccinated arm (difference: 6.4 percentage-points, 95% CI -8.2–21.2) (Figure 2A). For patients with stage IV melanoma, 3-year OS was 65.7% (95% CI 47.9–80.8) in the vaccinated arm and 49.2% (95% CI 34.2–64.1) in the unvaccinated arm (difference: 16.5 percentage-points, 95% CI -5.6–36.8) (Figure 2B). PFS at 3 years for patients with stage IV melanoma was 34.7% (95% CI 21.4–48.5) in the vaccinated arm compared with 29.5% (95% CI 15.3–43.9) in the unvaccinated arm (difference: 5.2 percentage-points, 95% CI -14.5–25.4) (Figure 2C).

Discussion

We emulated a hypothetical target trial to estimate the effect of COVID-19 vaccination during ICI treatment on overall and progression-free survival, using suitable causal inference methods. Contrary to the conclusions of Grippin *et al*,[1] our results do not give evidence that COVID-19

vaccination decreases the risk of death or progression in patients with NSCLC or stage IV melanoma treated with ICIs.

The original findings are susceptible to three major sources of bias, which may explain the discrepancies with our results. First, the time of eligibility, treatment assignment, and start of follow-up were not aligned in the original study.[2] In particular, the vaccinated group included patients who received vaccine within 100 days following baseline ICI injection. Thus, vaccinated patients were guaranteed to be event-free (immortal) up to the time they received the vaccine, leading to so-called immortal time bias.[5] The authors tried to assess such bias by excluding events occurring in the first 100 days. Unfortunately, this additional analysis induces another form of time-related bias, because the time of eligibility and start of follow-up (100 days post ICI) would occur after treatment assignment.[2] Furthermore, the start of follow-up time was not aligned in the vaccinated and unvaccinated groups in the NSCLC cohort: this time was set at the date of first ICI for the unvaccinated group, and at the date of last ICI prior to vaccination in the vaccinated group. This misalignment can lead to selection of patients having survived longer in the vaccinated group, again resulting in bias. Unlike the original study, we aligned the time of eligibility, treatment assignment and the start of follow-up for all patients: this time was fixed to the date of the first ICI.

Second, the authors originally included patients from 2015, more than five years before the COVID-19 vaccines were first available (December 2020). Patients diagnosed before 2020 had a zero probability of being vaccinated. This leads to positivity violations[6] and to confounding bias[7] as ICI indications broadened between 2015 and 2022 to include less advanced disease.[8]

Third, there were potential issues with the statistical adjustment for confounding variables. This adjustment was made through multivariable Cox modelling in the main data and propensity score matching in extended data. The choice of the confounding variables was driven by the significance of the association between the covariate and the outcome in univariable Cox proportional hazard models. This procedure selects strong predictors of the outcome, which might not be strong confounders.[9] Instead, confounding covariates should be selected based on expert knowledge, *e.g.*, visualized in a causal directed acyclic graph.[7] Also, among the selected

covariates, steroid use was defined using post-baseline information, which can result in collider stratification bias.[10] Furthermore, hazard ratios are hard to interpret as measures of causal effects, and adjusted hazard ratios from multivariable models do not reflect effects in the marginal population, due to non-collapsibility.[11–13]

While addressing key problems of the original study, our analysis also has limitations. It might be prone to residual unmeasured confounding bias, for example from time-varying confounders such as side effects of ICI treatment, which were not available. There could also be bias due to misspecification of models for the inverse probability of censoring weights. Furthermore, given the available data, we could not emulate a target trial for influenza or pneumonia vaccines, which could serve as a negative control exposure[14] as attempted by Grippin *et al.* in the original investigations.

Overall, our results give no evidence of a beneficial survival effect of COVID-19 vaccine during ICI treatment, contrary to the claims by Grippin et al. However, we cannot exclude that there is a genuine effect of COVID-19 vaccines on cancer outcomes, perhaps of lower magnitude, that is impossible to detect with the given dataset. Thus, we encourage future studies that apply causal inference methods to new, large-scale data to clarify the effect of COVID-19 mRNA vaccination in cancer patients treated with ICIs.

References

1. Grippin AJ, Marconi C, Copling S, et al: SARS-CoV-2 mRNA vaccines sensitize tumours to immune checkpoint blockade. Nature 1–10, 2025

2. Hernán MA, Sauer BC, Hernández-Díaz S, et al: Specifying a target trial prevents immortal time bias and other self-inflicted injuries in observational analyses. J Clin Epidemiol 79:70–75, 2016

3. Cashin AG, Hansford HJ, Hernán MA, et al: Transparent reporting of observational studies emulating a target trial: the TARGET Statement [Internet], 2025[cited 2025 Nov 2] Available from: https://www.bmj.com/content/390/bmj-2025-087179

4. Maringe C, Benitez Majano S, Exarchakou A, et al: Reflection on modern methods: trial emulation in the presence of immortal-time bias. Assessing the benefit of major surgery for elderly lung cancer patients using observational data. International Journal of Epidemiology 49:1719–1729, 2020

5. Suissa S: Immortal Time Bias in Pharmacoepidemiology. American Journal of Epidemiology 167:492–499, 2008

6. Petersen ML, Porter KE, Gruber S, et al: Diagnosing and responding to violations in the positivity assumption. Stat Methods Med Res 21:31–54, 2012

7. Hernán MA, Robins JM: Causal Inference: What If Boca Raton: Chapman&Hall/CRC. 2020

8. Gougis P, Jochum F, Abbar B, et al: Clinical spectrum and evolution of immune-checkpoint inhibitors toxicities over a decade—a worldwide perspective. eClinicalMedicine 70:102536, 2024

9. Witte J, Didelez V: Covariate selection strategies for causal inference: Classification and comparison. Biometrical Journal 61:1270–1289, 2019

10. Digitale JC, Martin JN, Glidden DV, et al: Key concepts in clinical epidemiology: collider-conditioning bias. Journal of Clinical Epidemiology 161:152–156, 2023

11. Hernán MA: The Hazards of Hazard Ratios. Epidemiology 21:13–15, 2010

12. Dumas E, Stensrud MJ: How hazard ratios can mislead and why it matters in practice. European Journal of Epidemiology 40:603–609, 2025

13. Stensrud MJ, Hernán MA: Why Test for Proportional Hazards? JAMA 323:1401–1402, 2020

14. Lipsitch M, Tchetgen ET, Cohen T: Negative Controls: A Tool for Detecting Confounding and Bias in Observational Studies. Epidemiology 21:383–388, 2010

Table 1: Specification and emulation of a target trial of COVID-19 vaccines during ICI treatment in patients with NSCLC or melanoma cancer from the data presented in Grippin *et al.* *It was unclear in the data if the patients without a COVID-19 vaccine were never vaccinated throughout follow-up or only within 100 days. **In the NSCLC cohort, the variables used for adjustment were : gender, ethnicity, age at ICI start (numeric), English as primary language, ECOG, heart disease, immune deficiency, diabetes, respiratory condition, chronic kidney disease (CKD), central nervous system (CNS) disease, and liver failure. In the melanoma cohort for overall survival, the variables used for adjustment were : gender, ethnicity, age at ICI start (numeric), English as primary language, ECOG, heart disease, immune deficiency, diabetes, respiratory condition, previous history of malignant at ICI start, and CKD. In the melanoma cohort for progression-free survival, the variables used for adjustment were: gender, age at ICI start (numeric), ECOG, heart disease, immune deficiency, diabetes, respiratory condition, previous history of malignant at ICI start, and CKD. The three adjustment sets differed slightly because we omitted variables leading to convergence issues due to small sample sizes in the logistic model used to estimate the weights. To avoid convergence issues in the model, the ethnicity variable was recoded as a binary variable: "caucasian" versus "non-caucasian". One included patient in the NSCLC cohort and two included patients in the melanoma cohort had age at ICI initiation coded as ">89". We imputed age at 90 for these three patients. ***These assumptions will be discussed in detail in a future work (Gasparollo et al., forthcoming).

Protocol	Target trial specification	Target trial emulation
Eligibility criteria	For NSCLC: patients diagnosed with stage III or stage IV NSCLC confirmed by biopsy after the COVID-19 vaccine were available and before September 2022, initiating ICI treatment. For melanoma: patients diagnosed with stage IV melanoma after the COVID-19 vaccine were available and before September 2022, initiating ICI treatment. Baseline is defined as the date of first ICI treatment.	Same as for the target trial. The COVID-19 vaccines were first available in December 2020. Therefore, we included patients initiating ICI in 2020, 2021, and 2022. We excluded patients who entered the original cohort after their first ICI initiation. We also excluded patients with missing ECOG data and assumed that ECOG missingness was completely at random.
Treatment strategies	(i) get a COVID-19 vaccine within 100 days of the first injection of ICI. The choice of vaccine and the date of the injection is left at the choice of the physician and patients. (ii) do not get a COVID-19 vaccine within 100 days of the first injection of ICI.	Same as for the target trial.*

Treatment assignment	Individuals are randomly assigned to a strategy at baseline, and individuals and their treating physicians will be aware of the assigned treatment strategy.	We cloned patients at baseline into two copies, one for each strategy, then artificially censored the clones if and when the behaviour of the patient was no longer consistent with the strategy assigned to the clone. Since the precise date of vaccination was not available in the data, we censored all vaccinated patients in the no vaccine arm at 100 days. We then re-weighted the clones using inverse probability of censoring (IPC) weights to adjust for baseline confounding covariates. IPC weights were set to 1 during the grace period (100 days) for all patients, and were then updated once, at the end of the grace period, for patients still at risk. The probability of remaining uncensored was estimated using a logistic regression model fitted on the confounding covariates. Confounding covariates were chosen based on expert knowledge and included socio-demographic variables and comorbid conditions.** Time-varying confounding covariates were not available in the data.
Outcomes	For NSCLC: overall survival (OS) For melanoma: overall survival and progression-free survival (PFS).	Same as in the target trial. OS and PFS were defined as done in the analysis of Grippin *et al*. (PFS was a composite outcome of progression and death)
Follow-up	Starts at baseline (ICI initiation) and ends in September 2024.	Same as in the target trial.
Causal contrasts	Per-protocol effect	Same as in the target trial.

Statistical analysis	Censor individuals if and when they deviate from their assigned treatment strategy and apply inverse-probability weights to adjust for baseline and time-varying confounding factors. No adjustment for administrative censoring, which is considered non-informative.	Same as in the target trial, except that adjustment is made for baseline confounding factors only, since time-varying confounding factors were not available in the data (see treatment assignment). We estimated weighted Kaplan-Meier survival curves and reported OS and PFS at 36 months (3 years). We used the non-parametric bootstrap with 1,000 iterations to estimate the 95% CIs based on percentiles. Patients included in 2022 had 24 months of maximum follow-up. Consequently, after 24 months of follow-up, the survival curves require extra assumptions about non-informative censoring to have a valid causal interpretation.*** Analyses were conducted with R version 4.5.0.

Figure 1: Study flowchart (A) for the NSCLC cohort and for (B) the stage IV melanoma cohort.



Figure 2: Adjusted Kaplan-Meier survival curves, risk tables, and estimates after 3 years for (i) NSCLC – overall survival, (ii) stage IV melanoma - overall survival, and (iii) stage IV melanoma – progression-free survival. In the risk tables, we present the numbers at risk after cloning but before weighting the patients. The vertical error bars at 12, 24 and 36 months represent confidence intervals around the curves at 1, 2 and 3 years, respectively. Abbreviations: OS: overall survival, PFS: progression-free survival, ICI: immune checkpoint inhibitors.